Overview
- Dermatology leaders emphasize proactive, early intervention, with clinicians reporting IL‑23–targeted biologics achieving skin‑clearance rates above 90%.
- Mexican experts report that misinformation and stigma delay care, as the Fundación Mexicana para la Dermatología estimates more than 2.5 million people in the country live with psoriasis.
- The WHO and National Psoriasis Foundation estimate that about 30% of patients may develop psoriatic arthritis, reinforcing calls for early, multidisciplinary management.
- IFPA’s October 29 observance highlights that more than 125 million people worldwide are affected and urges policies to expand access to effective treatments.
- Coverage cites a prevalence of roughly 2–3% in Argentina—over a million people—while costs and uneven insurance coverage continue to limit use of advanced biologics.